Methods/design
▪ Active psychiatric disorder, hypersensitivity, leukocytosis, hyperkalemia
ALEUKOCYTOSIS, DIABETIC KETOACIDOSIS, BOWEL OBSTRUCTION, INTESTINAL NECROSIS, THROMBOCYTOSIS, ILEUS, HYPERSENSITIVITY
The KBindER study (KAll study procedures were approved by the University of California, Irvine Institutional Review Board (protocol HS# 2020–5780, approval date August 6, 2020; latest version April 2, 2021). Inclusion and exclusion criteria are summarized in Table Inclusion and exclusion criteria for the KBindER study▪ Plasma K▪ Age ≥ 18 years▪ English or Spanish speaking▪ Patient able to provide written informed consent▪ Recent Bowel Surgery▪ Ileus or bowel obstruction▪ Received a dose of an oral potassium binder in past 48 h▪ Hemolyzed blood specimen as indicated by the laboratory▪ Severe leukocytosis or thrombocytosis▪ Pregnancy▪ Active psychiatric disorder▪ Diabetic ketoacidosis or hyperkalemia caused by any condition for which a therapy directed against the underlying cause is expected to correct the hyperkalemia▪ Dialysis session expected within 4 h after randomization▪ History or hypersensitivity to any of the study drugs▪ Concurrent use of sorbitol (due to increased risk of intestinal necrosis when used with SPS)